|
|
|
Insider
Information: |
Bancroft Charles A |
Relationship: |
Director |
City: |
New York |
State: |
NY |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
3 |
|
Direct
Shares |
168,937 |
|
Indirect Shares
|
300,000 |
|
|
Direct
Value |
$6,424,696 |
|
|
Indirect Value
|
$12,702,000 |
|
|
Total
Shares |
468,937 |
|
|
Total
Value |
$19,126,696 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
0
|
0
|
Stock
price went up :
|
0
|
0
|
Stock
price went down : |
0
|
0
|
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
Percentage
Gain/Loss : |
0.0%
|
0.0%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Bristol-Myers Squibb Co |
BMY |
EVP, Head of Integration |
2020-03-10 |
137,534 |
2020-03-10 |
300,000 |
Premium* |
|
Colgate Palmolive Co |
CL |
Director |
2018-05-14 |
5,455 |
2017-05-15 |
0 |
Premium* |
|
Kodiak Sciences Inc. |
KOD |
Director |
2020-04-02 |
25,948 |
|
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
117 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 5 of 5
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
BMY |
Bristol-Myers Squibb Co |
EVP & Chief Financial Officer |
|
2018-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
91,318 |
363,739 |
0 |
- |
|
BMY |
Bristol-Myers Squibb Co |
EVP & Chief Financial Officer |
|
2018-03-10 |
4 |
A |
$0.00 |
$0 |
D/D |
3,469 |
302,298 |
0 |
- |
|
BMY |
Bristol-Myers Squibb Co |
EVP & Chief Financial Officer |
|
2018-12-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,401 |
206,117 |
0 |
- |
|
BMY |
Bristol-Myers Squibb Co |
EVP & Chief Financial Officer |
|
2018-12-02 |
4/A |
OE |
$0.00 |
$0 |
D/D |
6,401 |
342,522 |
0 |
- |
|
BMY |
Bristol-Myers Squibb Co |
EVP & Chief Financial Officer |
|
2018-12-02 |
4/A |
D |
$53.46 |
$145,197 |
D/D |
(2,716) |
339,806 |
0 |
- |
|
BMY |
Bristol-Myers Squibb Co |
EVP & Chief Financial Officer |
|
2018-12-02 |
4 |
D |
$53.46 |
$145,197 |
D/D |
(2,716) |
203,401 |
0 |
- |
|
BMY |
Bristol-Myers Squibb Co |
EVP & Chief Financial Officer |
|
2019-02-28 |
4 |
OE |
$17.51 |
$925,999 |
D/D |
52,884 |
392,690 |
0 |
- |
|
BMY |
Bristol-Myers Squibb Co |
EVP & Chief Financial Officer |
|
2019-02-28 |
4 |
D |
$51.93 |
$1,548,189 |
D/D |
(29,813) |
362,877 |
0 |
- |
|
BMY |
Bristol-Myers Squibb Co |
EVP & Chief Financial Officer |
|
2019-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
62,255 |
411,547 |
0 |
- |
|
BMY |
Bristol-Myers Squibb Co |
EVP & Chief Financial Officer |
|
2019-03-10 |
4 |
D |
$0.00 |
$0 |
D/D |
(4,735) |
376,895 |
0 |
- |
|
BMY |
Bristol-Myers Squibb Co |
EVP & Chief Financial Officer |
|
2019-03-10 |
4 |
D |
$51.39 |
$1,254,070 |
D/D |
(24,403) |
395,994 |
0 |
- |
|
BMY |
Bristol-Myers Squibb Co |
EVP, Head of Integration |
|
2020-03-10 |
4 |
GD |
$0.00 |
$0 |
D/D |
300,000 |
92,309 |
0 |
- |
|
BMY |
Bristol-Myers Squibb Co |
EVP, Head of Integration |
|
2020-03-10 |
4 |
GA |
$0.00 |
$0 |
I/I |
300,000 |
300,000 |
0 |
- |
|
BMY |
Bristol-Myers Squibb Co |
EVP, Head of Integration |
|
2020-03-10 |
4 |
D |
$0.00 |
$0 |
D/D |
(397) |
106,408 |
0 |
- |
|
BMY |
Bristol-Myers Squibb Co |
EVP, Head of Integration |
|
2020-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
71,868 |
153,637 |
0 |
- |
|
BMY |
Bristol-Myers Squibb Co |
EVP, Head of Integration |
|
2020-03-10 |
4 |
A |
$0.00 |
$0 |
D/D |
7,075 |
158,045 |
0 |
- |
|
BMY |
Bristol-Myers Squibb Co |
EVP, Head of Integration |
|
2020-03-10 |
4 |
D |
$57.93 |
$1,930,286 |
D/D |
(33,321) |
137,534 |
0 |
- |
|
117 Records found
|
|
Page 5 of 5 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|